t(8;21)(q22;q22) RUNX1/RUNX1T1 by Kroes, Wilma & Stevens-Kroef, Marian
Leukaemia Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(2) 52 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
t(8;21)(q22;q22) RUNX1/RUNX1T1 
Wilma Kroes, Marian Stevens-Kroef 
Department of Clinical Genetics, Leiden University Medical Center, Leiden; Department of Human 
Genetics, Radboud university medical center, Nijmegen, The Netherlands. w.g.m.kroes@lumc.nl; 
Marian.Stevens-Kroef@radboudumc.nl 
Published in Atlas Database: May 2016 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0821ID1019.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68158/05-2016-t0821ID1019.pdf 
DOI: 10.4267/2042/68158
This article is an update of : 
Huret JL. t(8;21)(q22;q22). Atlas Genet Cytogenet Oncol Haematol 1997;1(1) 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Review on t(8;21)(q22;q22) RUNX1/RUNX1T1, 
with data on clinics, and the genes involved. 
Identity 
See figure below. 
t(8;21)(q22;q22) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen (top) and Diane H. Norback, Eric B. 
Johnson, Sara Morrison-Delap; R- banding (middle) - above: Jean Loup Huret; 2nd row: - Courtesy Christiane Charrin; 3rd and 
4th row: - Courtesy Roland Berger. Right: FISH - Courtesy Hossein Mossafa. 
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Translocation t(8;21) is found in 5-12% of AML. Among the non-random chromosomal aberrations observed in AML, 
t(8;21)(q22;q22) is one of the best known and usually correlates with AML M2, with well defined and specific morphological 
features. The common morphological features include the presence of large blast cells with abundant basophilic cytoplasm, often 
containing numerous azurophilic granulations; few blasts in some cases show very large granules (pseudo-Chediak-Higashi 
granules), suggesting abnormal fusion. Auer rods are frequently found. In addition to the large blast cells, there are also some 
smaller blasts, predominantly found in the peripheral blood. Promyelocytes, myelocytes and mature granulocytes with variable 
dysplasia are seen in the bone marrow. These cells may show abnormal nuclear segmentation and/or cytoplasmic staining 
defects including homogeneous pink colored cytoplasm - Text and iconography Courtesy Georges Flandrin 2001. 
 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML) with 
t(8;21)(q22;q22) is part of the Group of AML with 
recurrent genetic abnormalities. 
Phenotype/cell stem origin 
M2 mostly, rarely: M1 or M4 
Epidemiology 
Annual incidence: 1/106; 5% of AML, 10% of prior  
AML M2 (FAB classification). The most frequent 
anomaly in chilhood AML; seen in children and 
adults: mean age 30yrs, rare in elderly patients. 
Clinics 
Myeloid sarcomas may be present at presentation. 
Prognosis 
Complete remission (CR) in most cases (90%) with 
relatively long disease-free survival when treated 
with high dose chemotherapy. 
Cytology 
See figure and legend. 
 
t(8;21)(q22;q22): cohybridization experiments using dJ155L8 (RUNX1T1) and dJ1107L6 (RUNX1 ); note the splitting of RUNX1 
and colocalization on der(8) with RUNX1T1 - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. 
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RUNX1 and RUNX1T1 breakpoints in the t(8;21) / 5' RUNX1 - 3' RUNX1T1 fusion gene, and FISH - Courtesy Hossein Mossafa. 
 
Cytogenetics 
Cytogenetics molecular 
Cases with cryptic molecular translocation have 
been detected --> FISH use may be relevant. 
Additional anomalies 
Sole anomaly in only 20-30%; additional anomalies: 
loss of Y or X chromosome in half cases (1 X must 
be present), del(7q) or -7, +8, del (9q): 10% each. 
Variants 
Complex t(8;21;Var) involving a (variable) third 
chromosome have been described in 3%; part from 
chromosome 21 goes on der(8), part of the 8 on der 
(Var), and part of Var on der(21); therefore, the  
 
crucial event lies on der(8). 
Genes involved and 
proteins 
RUNX1T1 (runt-related transcription 
factor 1; translocated to, 1 (cyclin D-
related)) 
Location 
8q21.3 
DNA/RNA 
Transcription is from telomere to centromere. 
Protein 
3 proline rich domains, 2 Zn fingers, and in C-term, 
a PEST region; tissue restricted expression; nuclear 
localisation; putative transcription factor. 
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RUNX1 (runt-related transcription 
factor 1 (acute myeloid leukemia 1; 
aml1 oncogene)) 
Location 
21q22.12 
DNA/RNA 
Transcription is from telomere to centromere. 
Protein 
Contains a Runt domain and, in the C-term, a 
transactivation domain; forms heterodimers; widely 
expressed; nuclear localisation; transcription factor 
(activator) for various hematopoietic-specific genes. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' RUNX1 - 3' RUNX1T1; breakpoints: at the very 
5' end of RUNX1T1, between exons 5 and 6 in 
RUNX1. 
Detection 
Karyotyping, RT-PCR and FISH for cases of typical 
cell morphology, but apparently without the t(8;21); 
RT-PCR for minimal residual disease detection 
Fusion protein 
Description 
The N-term runt domain from RUNX1 is fused to the 
577 C-term residues from RUNX1T1; reciprocal 
product not detected; probable DNA binding role; 
the fusion protein retains the ability to recognize the 
RUNX1 concensus binding site (--> negative 
dominant competitor with the normal RUNX1) and 
to dimerize with the CBFb subunit. 
Oncogenesis 
Probable altered transcriptional regulation of normal 
RUNX1 target genes. 
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